Related Experiment Video
Updated: May 12, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
CD40 immunotherapy for pancreatic cancer
Robert H Vonderheide1, David L Bajor, Rafael Winograd
1Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA. rhv@exchange.upenn.edu
Abstract:
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive and lethal cancer which is poorly responsive to standard therapies. Although the PDA tumor microenvironment is considered especially immunosuppressive, recent data mostly from genetically engineered and other mouse models of the disease suggest that novel immunotherapeutic approaches hold promise. Here, we describe both laboratory and clinical efforts to target the CD40 pathway for immunotherapy in PDA. Findings suggest that CD40 agonists can mediate both T-cell-dependent and T-cell-independent immune mechanisms of tumor regression in mice and patients. T-cell-independent mechanisms are associated with macrophage activation and the destruction of PDA tumor stroma, supporting the concept that immune modulation of the tumor microenvironment represents a useful approach in cancer immunotherapy.
Insights
Targeting the CD40 pathway shows promise for pancreatic cancer immunotherapy. CD40 agonists activate immune cells and modify the tumor microenvironment, leading to tumor regression in both mice and patients.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDA) is an aggressive cancer with poor response to conventional treatments.
- The PDA tumor microenvironment is highly immunosuppressive, limiting the efficacy of current therapies.
- Emerging research suggests immunotherapy, particularly targeting the CD40 pathway, holds potential for PDA treatment.
Purpose of the Study:
- To investigate the therapeutic potential of targeting the CD40 pathway in pancreatic ductal adenocarcinoma.
- To evaluate both laboratory and clinical efficacy of CD40 agonists in PDA immunotherapy.
- To elucidate the immune mechanisms underlying CD40-mediated tumor regression in PDA.
Main Methods:
- Utilized genetically engineered and other mouse models of PDA.
- Conducted laboratory studies and clinical trials involving CD40 agonists.
- Analyzed immune responses, including T-cell-dependent and T-cell-independent mechanisms.
Main Results:
- CD40 agonists demonstrated efficacy in mediating tumor regression in both preclinical models and human patients.
- Observed both T-cell-dependent and T-cell-independent immune mechanisms contributing to tumor destruction.
- T-cell-independent mechanisms involved macrophage activation and degradation of the PDA tumor stroma.
Conclusions:
- Targeting the CD40 pathway represents a promising immunotherapeutic strategy for pancreatic ductal adenocarcinoma.
- Immune modulation of the tumor microenvironment via CD40 agonists can overcome PDA's resistance to therapy.
- CD40-targeted immunotherapy offers a novel approach to enhance treatment outcomes for pancreatic cancer patients.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...